MAPT and Alzheimer disease: Acetylcholinesterase inhibitors (AChEIs) and NMDA receptor antagonists have been indicated for the treatment of AD; additionally, several anti-Aβ monoclonal antibodies and anti-Tau monoclonal antibodies have received approval from FDA for therapeutic use [3].